Literature DB >> 12439587

Dialysis and contrast media.

Sameh K Morcos1, Henrik S Thomsen, Judith A W Webb.   

Abstract

In a previous survey we revealed uncertainty among responders about (a) whether or not to perform hemodialysis in patients with severely reduced renal function who had received contrast medium; and (b) when to perform hemodialysis in patients on regular treatment with hemodialysis or continuous ambulatory dialysis who received contrast medium. Therefore, the Contrast Media Safety Committee of The European Society of Urogenital Radiology decided to review the literature and to issue guidelines. The committee performed a Medline search. Based on this, a report and guidelines were prepared. The report was discussed at the Ninth European Symposium on Urogenital Radiology in Genoa, Italy. Hemodialysis and peritoneal dialysis safely remove both iodinated and gadolinium-based contrast media. The effectiveness of hemodialysis depends on many factors including blood and dialysate flow rate, permeability of dialysis membrane, duration of hemodialysis and molecular size, protein binding, hydrophilicity, and electrical charge of the contrast medium. Generally, several hemodialysis sessions are needed to removal all contrast medium, whereas it takes 3 weeks for continuous ambulatory dialysis to remove the agent completely. There is no need to schedule the dialysis in relation to the injection of iodinated or MR contrast media or the injection of contrast agent in relation to the dialysis program. Hemodialysis does not protect poorly functioning kidneys against contrast-medium-induced nephrotoxicity. Simple guidelines are given.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439587     DOI: 10.1007/s00330-002-1629-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  19 in total

Review 1.  [Complications due to contrast agent administration: what has been confirmed in prevention?].

Authors:  E Schönenberger; M Mühler; M Dewey
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

Review 2.  Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.

Authors:  Fulvio Stacul; Aart J van der Molen; Peter Reimer; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Marie-France Bellin; Olivier Clement; Gertraud Heinz-Peer
Journal:  Eur Radiol       Date:  2011-08-25       Impact factor: 5.315

Review 3.  A review: Radiographic iodinated contrast media-induced thyroid dysfunction.

Authors:  Sun Y Lee; Connie M Rhee; Angela M Leung; Lewis E Braverman; Gregory A Brent; Elizabeth N Pearce
Journal:  J Clin Endocrinol Metab       Date:  2014-11-06       Impact factor: 5.958

4.  Dialyzability of gadodiamide in hemodialysis patients.

Authors:  Tomoya Saitoh; Kazumasa Hayasaka; Yoshiaki Tanaka; Tsutomu Kuno; Yuji Nagura
Journal:  Radiat Med       Date:  2006-07

Review 5.  Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2006-05-04       Impact factor: 5.315

6.  Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography.

Authors:  Yao-Min Hung; Shoa-Lin Lin; Shih-Yuan Hung; Wei-Chun Huang; Paul Yung-Pou Wang
Journal:  World J Cardiol       Date:  2012-05-26

Review 7.  Contrast-induced nephropathy: pathogenesis and prevention.

Authors:  Robert E Cronin
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

Review 8.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

9.  Clearance and safety of the radiocontrast medium iopamidol in peritoneal dialysis patients.

Authors:  Shingo Hatakeyama; Akihiko Abe; Takehiro Suzuki; Yasuhiro Hashimoto; Takuya Koie; Tomihisa Funyu; Shigeru Satoh; Tomonori Habuchi; Chikara Ohyama; Shigeki Matsuo
Journal:  Int J Nephrol       Date:  2011-10-19

10.  Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines.

Authors:  Aurang Z Khawaja; Deirdre B Cassidy; Julien Al Shakarchi; Damian G McGrogan; Nicholas G Inston; Robert G Jones
Journal:  Insights Imaging       Date:  2015-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.